ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Prognostic impact of neoadjuvant therapy and nomogram development in early-stage and locally advanced Siewert type II adenocarcinoma of the esophagogastric junction based on the SEER database.Journal of thoracic disease · 2026Article
- Tumor response to neoadjuvant treatment as a predictor of benefit for adjuvant treatment in esophago-gastric cancers: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Article
- Integrated Prognostic Stratification After Perioperative FLOT in Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicenter Real-World Study.Journal of clinical medicine · 2026Article
- Response-adapted perioperative therapy for resectable esophageal cancer in the immunotherapy era: a narrative review.Journal of thoracic disease · 2026Review
- Pathologic Response and Outcomes After Neoadjuvant Chemotherapy in Gastric Cancer: A NCDB Analysis.Journal of surgical oncology · 2026Article
- Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions.Medicina (Kaunas, Lithuania) · 2026Article
- MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapy.BMC cancer · 2026Article
- Prognostic Impact and Postoperative Management Following Poor Pathological Response to Perioperative FLOT in Resectable Gastric and GEJ Adenocarcinoma: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Neoadjuvant Chemotherapy for Gastric Cancer: Evolving Approaches and Supporting Evidence.Journal of gastric cancer · 2026Review
- Impact of postoperative chemotherapy in patients resected for esophagogastric adenocarcinoma with major pathological response after preoperative chemotherapy: a study from the FREGAT database.Therapeutic advances in medical oncology · 2026Article
- Is More Really Better? Intensive Neoadjuvant Therapy and Standard Perioperative FLOT for Locally Advanced Gastric Cancer Demonstrate Similar Short-Term Outcomes.Annals of surgical oncology · 2025Article
- Article
- Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the FLOT4 gastric cancer (GC) trial, the use of adjuvant chemotherapy has been perceived as limited and its added value questioned. We wanted to objectify this perception and reassess the value of adjuvant chemotherapy in a real-world setting.
methodsIn our retrospective cohort study we analyzed real-world data from 147 patients with GC or cancer of the gastroesophageal junction (AEG) who received perioperative FLOT. Data originated from clinical care at the university hospital, local hospitals and medical practices. Clinicopathologic data, survival outcomes, and targetable biomarkers were analyzed.
resultsMedian overall survival (OS) and tumor specific survival (TSS) were 19.4 ± 2.9 and 19.9 ± 3.1 months, respectively. 84.4% completed all cycles of neoadjuvant chemotherapy. The pathological complete response rate was 11.8%. Adjuvant chemotherapy was initiated in only 42.9%. Survival rates of patients with marked tumor regression (TRG1) were not improved by adjuvant chemotherapy. Conversely, patients with partial histopathologic response (TRG2) showed a marked trend and those with minimal histopathologic response (TRG3) showed a significantly longer survival with any number of adjuvant chemotherapy cycles (OS: 22.3 ± 2.6 months versus 8.7 ± 2.4 months, p = 0.005; TSS: 22.3 ± 4.5 months versus 8.7 ± 2.4 months, p = 0.016). Targetable biomarkers PD-L1, Claudin 18.2, HER2 and microsatellite instability were detected in 53.4%, 26.2%, 7.8%, and 3.9% of the TRG2/3 patient subset, respectively.
conclusionsIn the real-world setting, adjuvant chemotherapy proved to be a critical turning point of the FLOT regimen. It should be sought-even in a reduced form-in patients with TRG2/3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.